Gilead Sciences, Inc.
CH ˙ SWX ˙ US3755581036
SecurityCH:GILD / Gilead Sciences, Inc.
InstitutionDriehaus Capital Management Llc
Latest Disclosed Ownership4,085 shares
Latest Disclosed Value $ 569,326
Driehaus Capital Management Llc reports 18.84% decrease in ownership of GILD / Gilead Sciences, Inc.

On May 15, 2026 - Driehaus Capital Management Llc filed a 13F-HR form disclosing ownership of 4,085 shares of Gilead Sciences, Inc. (CH:GILD) valued at $569,326 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 5,033 shares of Gilead Sciences, Inc.. This represents a change in shares of -18.84% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F Gilead Sciences COM 375558103 4,085 -948 -18.84 569 -7.78 0.0042
2026-02-17 2025-12-31 13F Gilead Sciences COM 375558103 5,033 5,033 618 0.0042
2024-05-15 2024-03-31 13F GILEAD SCIENCES COM 375558103 0 -2,513 -100.00 0 -100.00
2024-02-14 2023-12-31 13F GILEAD SCIENCES COM 375558103 2,513 2,513 204 0.0025
2022-05-16 2022-03-31 13F GILEAD SCIENCES COM 375558103 0 -3,444 -100.00 0 -100.00
2022-02-14 2021-12-31 13F GILEAD SCIENCES COM 375558103 3,444 3,444 250 0.0026
2020-08-14 2020-06-30 13F GILEAD SCIENCES COM 375558103 0 -31,300 -100.00 0 -100.00
2020-05-15 2020-03-31 13F GILEAD SCIENCES COM 375558103 31,300 31,300 2,340 0.0782
2015-02-13 2014-12-31 13F GILEAD SCIENCES COM 375558103 0 -44,292 -100.00 0 -100.00
2014-11-14 2014-09-30 13F GILEAD SCIENCES COM 375558103 44,292 -86,872 -66.23 4,715 -56.64 0.1797
2014-08-14 2014-06-30 13F Gilead Sciences COM 375558103 131,164 -130,082 -49.79 10,875 -41.25 0.3528
2014-05-15 2014-03-31 13F Gilead Sciences COM 375558103 261,246 11,153 4.46 18,512 -1.50 0.5823
2014-02-13 2013-12-31 13F Gilead Sciences COM 375558103 250,093 97,410 63.80 18,794 95.87 0.6782
2013-11-14 2013-09-30 13F Gilead Sciences COM 375558103 152,683 7,732 5.33 9,595 29.26 0.3705
2013-08-14 2013-06-30 13F Gilead Sciences COM 375558103 144,951 144,951 7,423 0.3244
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.